Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Michael O. Chaney is active.

Publication


Featured researches published by Michael O. Chaney.


Journal of Biological Chemistry | 1996

Morphology and Toxicity of Aβ-(1-42) Dimer Derived from Neuritic and Vascular Amyloid Deposits of Alzheimer's Disease

Alex E. Roher; Michael O. Chaney; Yu-Min Kuo; Scott D. Webster; W. Blaine Stine; Lanny J. Haverkamp; Amina S. Woods; Robert J. Cotter; James M. Tuohy; Grant A. Krafft; Barry S. Bonnell; Mark R. Emmerling

In the course of analyzing the chemical composition of Alzheimers disease neuritic and vascular amyloid, we have purified stable dimeric and trimeric components of Aβ peptides. These peptides (molecular mass 9.0 and 13.5 kDa) were separated by size exclusion chromatography in the presence of 80% formic acid or 5 M guanidine thiocyanate, pH 7.4. The average ratio of monomers, dimers, and trimers was 55:30:15, respectively. Similar structures were produced over time upon incubation of synthetic Aβ-(1-42) at pH 7.4. The stability of these oligomeric forms was also demonstrated by Western blot and mass spectrometry. Atomic force microscopy and electron microscopy rotary shadowing revealed that the monomers polymerized into 8-10-nm filaments, whereas the dimers generated prolate ellipsoids measuring 3-4 nm in diameter. The pathogenic effects of the dimeric Aβ-(1-40/42) were tested in cultures of rat hippocampal neuron glia cells. Only in the presence of microglia did the dimer elicit neuronal killing. It is possible that these potentially pathogenic Aβ-(1-40/42) dimers and trimers from Alzheimers disease amyloid represent the soluble oligomers of Aβ recently described in Alzheimers disease brains (Kuo, Y.-M., Emmerling, M. R., Vigo-Pelfrey, C., Kasunic, T. C., Kirkpatrick, J. B., Murdoch, G. H., Ball, M. J., and Roher, A. E. (1996) J. Biol. Chem., 271, 4077-4081).


Molecular Brain Research | 1991

Conservation of the sequence of the Alzheimer's disease amyloid peptide in dog, polar bear and five other mammals by cross-species polymerase chain reaction analysis

Edward M. Johnstone; Michael O. Chaney; Franklin H. Norris; R. Pascual; Sheila P. Little

Neuritic plaque and cerebrovascular amyloid deposits have been detected in the aged monkey, dog, and polar bear and have rarely been found in aged rodents (Biochem. Biophy. Res. Commun., 12 (1984) 885-890; Proc. Natl. Acad. Sci. U.S.A., 82 (1985) 4245-4249). To determine if the primary structure of the 42-43 residue amyloid peptide is conserved in species that accumulate plaques, the region of the amyloid precursor protein (APP) cDNA that encodes the peptide region was amplified by the polymerase chain reaction and sequenced. The deduced amino acid sequence was compared to those species where amyloid accumulation has not been detected. The DNA sequences of dog, polar bear, rabbit, cow, sheep, pig and guinea pig were compared and a phylogenetic tree was generated. We conclude that the amino acid sequence of dog and polar bear and other mammals which may form amyloid plaques is conserved and the species where amyloid has not been detected (mouse, rat) may be evolutionarily a distinct group. In addition, the predicted secondary structure of mouse and rat amyloid that differs from that of amyloid bearing species is its lack of propensity to form a beta sheeted structure. Thus, a cross-species examination of the amyloid peptide may suggest what is essential for amyloid deposition.


Biochemical and Biophysical Research Communications | 1973

Pyrazomycin B: Isolation and characterization of an α-C-nucleoside antibiotic related to pyrazomycin

Gerald E. Gutowski; Michael O. Chaney; Noel D. Jones; Robert L. Hamill; Fred A. Davis; Roger D. Miller

Abstract This communication reports the isolation and structure of pyrazomycin B, the α-anomer of the anti-tumor and anti-viral antibiotic pyrazomycin. Spectral, chemical and x-ray crystallographic evidence is provided.


Neurological Research | 2003

Aβ, aging, and Alzheimer's disease: A tale, models, and hypotheses

Michael O. Chaney; Jerome Baudry; Chera L. Esh; Jennifer Childress; Dean C. Luehrs; Tyler A. Kokjohn; Alex E. Roher

Abstract In this paper we explore the potential functional role of the Aβ peptides in the context of Alzheimers disease (AD). We begin by defining the morphology of the amyloid deposits in relation to surrounding glial cells and, more importantly, in relation to the brain vasculature. Amyloid accumulation in the brains microvasculature causes disturbances in the blood-brain barrier (BBB), and in larger arteries, impairment in control of regional cerebral blood flow due to myocyte degeneration. We postulate that the deposition of vascular amyloid may represent a hydrophobic protein plaster to seal leaks in the BBB, occasionally observed in aging and catastrophically common in AD. The vasoconstrictive activity of Aβ may also be related to leaky vessels whereby decreasing the arterial diameter may also help to control breaches in the BBB. The admission of plasma neurotoxic proteins into the brain may be controlled by activation of microglia elicited by soluble Aβ peptides creating a subtle, but permanent brain inflammatory reaction. We also delve into the influence that cholesterol metabolism may have in membrane topology and Aβ production, and the close correlations that exist between cardiovascular disease and AD. Finally, we speculate about the possibility of a peripheral source of Aβ that may, by crossing the BBB, contribute to the vascular and parenchymal deposits of Aβ in the AD brain.


Tetrahedron | 1999

Rapid parallel synthesis applied to the optimization of a series of potent nonpeptide neuropeptide Y-1 receptor antagonists

Miles Goodman Siegel; Michael O. Chaney; Robert F. Bruns; Michael P. Clay; Douglas A. Schober; Anne M. Van Abbema; Douglas W. Johnson; Buddy E. Cantrell; Patric James Hahn; David C. Hunden; Donald R. Gehlert; Hamideh Zarrinmayeh; Paul L. Ornstein; Dennis M. Zimmerman; Gary A. Koppel

Abstract This study describes the integrated application of parallel synthesis and computational chemistry to the design of potent nonpeptide antagonists for the neuropeptide Y-1 (NPY1) receptor. A lead molecule was modeled in the active site of the NPY1 receptor, and a potentially fruitful region for analog construction was identified. Synthesis of suitable scaffolds followed by solution phase generation of a small library of analogs produced a compound with 5-fold improvement in binding over the already potent lead. This new compound was shown to be an unanticipated side product of the parallel synthesis reaction.


Chemistry & Biology | 1995

Use of peptide combinatorial libraries in drug design: the identification of a potent serotonin reuptake inhibitor derived from a tripeptide cassette library

Gary A. Koppel; Carmen Dodds; Brenda Houchins; David C. Hunden; Douglas W. Johnson; Rebecca A. Owens; Michael O. Chaney; Theodore Usdin; Beth J. Hoffman; Michael J. Brownstein

BACKGROUND Medicinal chemistry traditionally requires the identification of biologically active molecules by synthesizing and screening each purified substrate. Further progress in drug discovery then requires definition of the structure-activity relationship of the lead compound. More recently, combinatorial chemistry has emerged as a way to examine structure-activity relationships by screening a large mixture of compounds synthesized in a predictably random manner, without the labor-intensive costs of molecular isolation and purification. We set out to use this approach to examine the structural requirements for peptide binding to serotonin and dopamine transporters. RESULTS We screened a tripeptide cassette library for serotonin and dopamine reuptake inhibition using cloned transporter assay systems. The method has afforded a number of tripeptide pharmacophores with inhibitory IC50 values ranging from 10 microM to < 1 microM in the dopamine and serotonin reuptake systems. The conformation of one of these tripeptides, N-acetyl-D-Trp-L-Phe-D-Lys-CONH2 (which inhibits serotonin uptake with an IC50 of 10 microM) was compared to that of the serotonin uptake inhibitor s-fluoxetine, and was shown to be more similar in conformation to fluoxetine than was an analogous tripeptide containing L-Lys (IC50 > 50 microM). CONCLUSIONS We have identified five tripeptides with inhibitory IC50 values of < 10 microM in the serotonin reuptake system. One tripeptide was predicted to have pharmacophore features similar to that of fluoxetine, a selective and potent non-peptide serotonin reuptake inhibitor. Our results suggest that tripeptides derived from combinatorial libraries will help to define the important structural elements of pharmacophores.


Biochemical and Biophysical Research Communications | 1989

Alzheimer's disease amyloid peptide is encoded by two exons and shows similarity to soybean trypsin inhibitor

Edward M. Johnstone; Michael O. Chaney; Robert E. Moore; Karen E. Ward; Franklin H. Norris; Sheila P. Little

To better understand the processing of the Alzheimer disease amyloid precursor protein, we have cloned and sequenced that region of the human genome coding for the amyloid peptide. Two exons separated by a 6.2kb intron define this region. Characterization of the A4 peptide amino acid sequence shows similarity to the structure of soybean trypsin inhibitor (Kunitz). Our observation describes a different region of PreA4 than the previously characterized domain of larger amyloid precursor molecules PreA4 751 and 770(2). Moreover, the exon organization, Kunitz domain duplication and transmembrane location of A4 suggest that PreA4 is similar to growth factor precursors and thus may be processed similarly.


Journal of Molecular Graphics | 1995

Visualization and comparison of molecular dynamics simulations of leukotriene C4, leukotriene D4, and leukotriene E4

David K. Herron; Nancy G. Bollinger; Michael O. Chaney; Alexander D. Varshavsky; Jeffery B. Yost; William R. Sherman; Jeffrey A. Thingvold

Molecular dynamics simulations of leukotriene C4 (LTC4), leukotriene D4 (LTD4), and leukotriene E4 (LTE4) were carried out, and the data were visualized in an animated video format. Three-dimensional ghost images show the positions of the heavy atoms of all three molecules throughout the simulations. The ghost images can be superimposed to give a single three-dimensional image in which the shapes of the most populated conformers of each molecule are apparent and can be compared. Leukotriene D4 was found to occupy mostly T-shaped conformations, while LTC4 occupied mostly cup-shaped conformations, and LTE4 occupied a wide range of conformations spanning the LTD4 and LTC4 types. Digital filtering and graphing of the internal geometries of the molecules as a function of time revealed differences in dynamic behavior. The results are discussed in light of current knowledge about leukotriene receptors.


Journal of The Chemical Society, Chemical Communications | 1978

Synthesis of a sym-oxepin oxide with restricted conformational mobility and altered reactivity. X-Ray crystal and molecular structure of 4,7-dibromo-3a,7a:5,6-diepoxyperhydroindene

William H. Rastter; Thomas J. Richard; Noel D. Jones; Michael O. Chaney

Nitrogen extrusion from the azo diepoxide (4) generates the sym-oxepin oxide (5a), the altered reactivity of which is attributed to the conformational rigidity of (5a) as compared to the parent molecule (2); bromination of the bridgehead diene (5a) gives the dibromo-diepoxide (8) whose structure has been verified by X-ray crystal structure analysis.


Journal of Pharmacology and Experimental Therapeutics | 1998

LY320135, a Novel Cannabinoid CB1 Receptor Antagonist, Unmasks Coupling of the CB1 Receptor to Stimulation of cAMP Accumulation

Christian C. Felder; Kelly E. Joyce; Eileen M. Briley; Michelle Glass; Ken Mackie; Kennan Joseph Fahey; George Joseph Cullinan; David C. Hunden; Douglas W. Johnson; Michael O. Chaney; Gary A. Koppel; Michael J. Brownstein

Collaboration


Dive into the Michael O. Chaney's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge